|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Acceleron Pharma Inc., of Cambridge, Mass., said preclinical data reported at the Gordon Research Conference on myogenesis in Lucca, Italy, demonstrated the ability of ACE-031 to increase muscle mass and strength in normal mice and in murine models of muscular dystrophy. The compound is designed to inhibit negative regulators of muscle to increase muscle mass and strength as a potential treatment for neuromuscular diseases and cancer-related muscle loss.
o Amura Holdings Ltd., of Cambridge, UK, said its lead cathepsin K inhibitors for osteoporosis and bone metastasis demonstrated good in vivo safety profiles in a seven-day, repeat-dose toxicity study in ...